Moderna and Merck say their personalized mRNA cancer vaccine cut death and recurrence by 42%, according to Ars Technica — the latest readout from the program that produced one of the most closely watched cancer trial results of the year.
The vaccine works as a personalized companion to Merck's immunotherapy Keytruda: a patient's tumor is sequenced, and the vaccine is built to carry neoantigens unique to that cancer, aiming to teach the immune system to hunt residual cells after surgery. Earlier this summer, the phase 3 trial in melanoma was reported to cut recurrence by roughly half — a landmark for the mRNA platform beyond infectious disease.
The new figures add the endpoint that matters most to patients: death. A combined reduction of 42% in death or recurrence keeps the effect large while extending it to overall survival — the number that turns a promising mechanism into a case for approval and adoption.
Messenger RNA proved itself at population scale against a pandemic. The open question has been whether that same manufacturing speed — read a genome, write a vaccine — could be turned against cancer's variability, where every patient's treatment is a one-off. Updated survival data is how that question gets answered, one trial at a time.
